BP11001 PLGA 75:25, Carboxyl-Terminated, IV ≥ 0.75 dl/g, Mw ≥ 106 kDa

PLGA 75:25, Carboxyl-Terminated, IV ≥ 0.75 dl/g, Mw ≥ 106 kDa Description

BP11001 represents a high-performance, carboxyl-terminated PLGA 75:25 copolymer within the high molecular weight and intrinsic viscosity spectrum (Mw ≥ 106 kDa, IV ≥ 0.75 dl/g). This material provides mechanical strength, high melt strength, and excellent dimensional stability, making it suitable for fabricating medical devices and scaffolds. The 75:25 ratio ensures a degradation period extending from several months to over a year. The terminal carboxyl groups enhance hydrophilicity, influence early-stage degradation kinetics, and serve as sites for covalent attachment of drugs, signalling molecules, or crosslinkers, enabling the development of bioactive implants.

PLGA 75:25, Carboxyl-Terminated, IV ≥ 0.75 dl/g, Mw ≥ 106 kDa Applications

1.         Long-Term Implantable & Structural Applications
- Sustained Drug Delivery Implants: Acts as the matrix in long-term implants (e.g., rods, stents) for controlled therapeutic release over 6-24 months. The carboxyl groups allow for drug conjugation or surface functionalisation.
- Load-Bearing Tissue Scaffolds: Used to fabricate scaffolds for bone and cartilage regeneration, providing mechanical support that degrades in sync with tissue healing.

2.         Advanced Functional Materials & Coatings
- Functionalised Coatings for Medical Devices: Applied as a coating on implants to modulate drug elution, improve biocompatibility, or enable bioactivation via carboxyl group chemistry.
- Reactive Polymer for Material Synthesis: Acts as a macroinitiator or building block for creating block copolymers, hydrogels, and composites with tailored degradation and mechanical properties.

PLGA 75:25, Carboxyl-Terminated, IV ≥ 0.75 dl/g, Mw ≥ 106 kDa Packing

The product is securely packaged in vacuum-sealed, multi-layer aluminised moisture-barrier pouches under an inert nitrogen atmosphere to prevent hydrolysis and oxidative degradation. Each primary pouch contains desiccant and is further protected within a rigid, insulated secondary container to ensure integrity during shipping and storage. Available in a range of sizes from small R&D quantities (e.g., 1g, 5g) to industrial-scale packaging. Custom packaging and labelling solutions are available.

Additional Information

This carboxyl-terminated, high molecular weight PLGA 75:25 is engineered for applications in regenerative medicine and drug delivery. It combines the lifecycle required for structural support with functionality needed for biointeraction. This duality enables the creation of implants that degrade on a predictable, multi-month timeline and can actively participate in the healing process through bioactivity.

Stanford Advanced Materials (SAM) specialises in providing high-specification, consistent polymer solutions for applications. Our technical support team is ready to collaborate on material selection, processing optimisation, and custom synthesis projects to meet your challenges.

Regulatory Note: This material is intended for research and industrial use. It is the customer's responsibility to ensure compliance with all applicable safety, regulatory, and quality standards for their specific application and region.